Bharat Biotech To Start Phase 2/3 Trials Of Covaxin On Children Aged 2-18
Indigenous vaccine maker Bharat Biotech will soon begin the phase 2/3 clinical trials of its COVID-19 vaccine 'Covaxin' on children aged between 2-18. The request for clinical trials was approved by the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation on May 11. The approval has been granted keeping in view the reports, which have indicated that the third wave is likely to be harsh on children.